Study of OM336 for low blood cell counts caused by immune system
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a condition where your immune system attacks your own blood cells, like low red cells, white cells, or platelets
- You have tried at least one prior treatment that did not work or stopped working
- You weigh at least 55 kg (about 121 pounds)
- You are willing to follow the study rules and scheduled visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
Hear when a new AIHA - Warm Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.